Weller 2017.

Study characteristics
Methods	Phase III randomised, double‐blind
Participants	First‐line glioblastoma patient: randomisation (1:1) ‐ 195 rindopepimut and temozolomide, 210 standard of care (temozolomide)
Interventions	Rindopepimut + temozolomide vs temozolomide
Outcomes	OS: HR 0.89, P = 0.22 (17.4 vs 17.4 months ITT analysis) PFS: HR 1.01 (8.0 vs 7.4 months) QoL: no difference Toxicity: Injection site reactions, transient grade 1 to 2 erythema, pruritus, rash Thrombocytopenia, fatigue, brain oedema, seizure, headache
Notes	Terminated early at second preplanned interim analysis – futility boundary crossed.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random assignment to treatment groups with a prespecified randomisation sequence with a block size of 4.
Allocation concealment (selection bias)	Low risk	Double‐blinded study – unblinded pharmacists obtained randomly assigned treatment assignments and managed study treatment via interactive response technology
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded study Placebo vaccine ‐ preloaded with immunostimulant
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Local assessors (blinded), central assessors (also blinded for PFS and ORR assessments)
Incomplete outcome data (attrition bias) All outcomes	Low risk	None
Selective reporting (reporting bias)	Unclear risk	None
Other bias	Low risk